SAN DIEGO, Aug. 11, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the "Class Period"), have until this upcoming Tuesday, August...
Related Questions
What is the potential financial impact of the lawsuit on Tempus AI's balance sheet and cash flow?
How likely is it that the class action will result in a settlement versus a trial, and what timeframe could that entail?
What is the estimated size of the potential settlement or judgment for investors in the class period?
How might this litigation affect Tempus AI's share price volatility in the short‑term (next few days) and medium‑term (weeks to months)?
Will the lawsuit trigger any credit rating downgrades or affect the company’s ability to raise capital?
Are there any similar past lawsuits against Temp- AI or its peers, and how were they resolved?
What specific allegations are being made (e.g., fraud, misrepresentation, securities law violations) and how strong are the legal claims?
How many investors are expected to join the class, and what is the total amount of alleged losses?
Could this lawsuit lead to changes in management, corporate governance, or strategic direction at Tempus AI?
What impact might the lawsuit have on existing partnerships, customer contracts, or supplier relationships?
Will this litigation affect any pending or upcoming financing transactions for Tempus AI?
How does the market's perception of this lawsuit compare to other recent litigation in the biotech/AI sector?
What are the potential regulatory or SEC implications for Tempus AI beyond the class action?
What is the deadline for investors to join the class, and what steps must they take?